"The ongoing Coronavirus (COVID-19) pandemic is re-shaping everything from global economies to product categories, pricing, and stock availability to the consumer behavior. The final report is updated to address the impact of COVID-19 on the Alpha Thalassemia market. Trusted Business Insights is tracking mining/oil and gas, transportation, employment services, travel arrangements, and the leisure and hospitality sector closely as they are likely to be the hardest-hit sectors. Utilities, local pharma, diagnostics, consumer goods and durables, agro chem and fertilizers, and telecommunications are the sectors that will be weathering the COVID-19 storm and most likely come out relatively unscathed. Interdependencies of sectors are factored in our research report on the Alpha Thalassemia market." Thalassemia is a general term for a group of inheritable blood disorders, in which the body produces abnormal hemoglobin, resulting in destruction of red blood cells. This ultimately leads to anemia. There are two main types of thalassemia: alpha-thalassemia and beta-thalassemia, the latter being more serious. Beta-thalassemia is a common autosomal recessive disorder worldwide and it is relatively rare in U.S. The global Alpha Thalassemia market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. This report focuses on Alpha Thalassemia volume and value at global level, regional level and company level. From a global perspective, this report represents overall Alpha Thalassemia market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan. At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report. The following manufacturers are covered: Bluebird Bio Novartis Kiadis Pharma Acceleron Pharma ... Segment by Regions North America Europe China Japan Segment by Type Iron Chelating Drugs Gene Therapy Segment by Application Hospitals Private clinics Other
Table of Contents Executive Summary 1 Alpha Thalassemia Market Overview 1.1 Product Overview and Scope of Alpha Thalassemia 1.2 Alpha Thalassemia Segment by Type 1.2.1 Global Alpha Thalassemia Production Growth Rate Comparison by Type (2014-2025) 1.2.2 Iron Chelating Drugs 1.2.3 Gene Therapy 1.3 Alpha Thalassemia Segment by Application 1.3.1 Alpha Thalassemia Consumption Comparison by Application (2014-2025) 1.3.2 Hospitals 1.3.3 Private clinics 1.3.4 Other 1.4 Global Alpha Thalassemia Market by Region 1.4.1 Global Alpha Thalassemia Market Size Region 1.4.2 North America Status and Prospect (2014-2025) 1.4.3 Europe Status and Prospect (2014-2025) 1.4.4 China Status and Prospect (2014-2025) 1.4.5 Japan Status and Prospect (2014-2025) 1.5 Global Alpha Thalassemia Market Size 1.5.1 Global Alpha Thalassemia Revenue (2014-2025) 1.5.2 Global Alpha Thalassemia Production (2014-2025) 2 Global Alpha Thalassemia Market Competition by Manufacturers 2.1 Global Alpha Thalassemia Production Market Share by Manufacturers (2014-2019) 2.2 Global Alpha Thalassemia Revenue Share by Manufacturers (2014-2019) 2.3 Global Alpha Thalassemia Average Price by Manufacturers (2014-2019) 2.4 Manufacturers Alpha Thalassemia Production Sites, Area Served, Product Types 2.5 Alpha Thalassemia Market Competitive Situation and Trends 2.5.1 Alpha Thalassemia Market Concentration Rate 2.5.2 Alpha Thalassemia Market Share of Top 3 and Top 5 Manufacturers 2.5.3 Mergers & Acquisitions, Expansion 3 Global Alpha Thalassemia Production Market Share by Regions 3.1 Global Alpha Thalassemia Production Market Share by Regions 3.2 Global Alpha Thalassemia Revenue Market Share by Regions (2014-2019) 3.3 Global Alpha Thalassemia Production, Revenue, Price and Gross Margin (2014-2019) 3.4 North America Alpha Thalassemia Production 3.4.1 North America Alpha Thalassemia Production Growth Rate (2014-2019) 3.4.2 North America Alpha Thalassemia Production, Revenue, Price and Gross Margin (2014-2019) 3.5 Europe Alpha Thalassemia Production 3.5.1 ... | read more...